Gyre Therapeutics
GYRE
29 hedge funds and large institutions have $4.9M invested in Gyre Therapeutics in 2016 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 9 reducing their positions, and 4 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
6% less funds holding
Funds holding: 31 → 29 (-2)
22% less capital invested
Capital invested by funds: $6.31M → $4.9M (-$1.41M)
50% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 4
78% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 9
Top Buyers
| 1 |
Renaissance Technologies
New York
|
+$114K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$24.6K |
| 3 |
WS
Wedbush Securities
Los Angeles,
California
|
+$10.1K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$2.11K |
Top Sellers
| 1 |
BI
BVF Inc
San Francisco,
California
|
-$141K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$47.4K |
| 3 |
DCM
DG Capital Management
New York
|
-$36.5K |
| 4 |
Morgan Stanley
New York
|
-$18.1K |
| 5 |
Goldman Sachs
New York
|
-$10.7K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
26
Morgan Stanley
New York
| – | -$18.1K | -120 | -99% |
|
27
Group One Trading
Chicago,
Illinois
| – | -$4K | -24 | Closed |
|
28
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| – | -$2K | -14 | Closed |
|
|
BA
29
BlackRock Advisors
Wilmington,
Delaware
| – | -$1K | -5 | Closed |
|
|
TRCT
30
Tower Research Capital (TRC)
New York
| – | -$1K | -4 | Closed |
|
GYRE Hedge Fund Activity: Q3 2016 in Review
29 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Gyre Therapeutics (GYRE) for Q3 2016, worth a combined $4.9M — down 22% from $6.31M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of GYRE and 2 opened new positions — a net loss of 2 holders — while 9 trimmed existing stakes and 2 added.
The largest buyer was Renaissance Technologies, adding an estimated $114K. The largest seller was BVF Inc, cutting an estimated $141K.
- 29 institutional investors held Gyre Therapeutics (GYRE) as of Q3 2016, down from 31 in Q2 2016.
- Funds reported $4.9M of Gyre Therapeutics stock for Q3 2016, down 22% quarter-over-quarter.
- 2 funds opened new Gyre Therapeutics positions in Q3 2016 and 4 closed out, a net change of -2 holders.
- The largest Gyre Therapeutics buyer in Q3 2016 was Renaissance Technologies, an estimated $114K added.
- The largest Gyre Therapeutics seller in Q3 2016 was BVF Inc, an estimated $141K sold.
Based on aggregated 13F filings for Q3 2016.